Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings ...

Medtronic beat quarterly expectations Tuesday, but Medtronic stock dipped near a sell zone in premarket trading.

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues ...

Medtronic — the world's largest medical device company — is preparing for potential new import taxes and other policy changes ...

With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...

The latest trading day saw Medtronic (MDT) settling at $87.53, representing a +1.78% change from its previous close.

Medtronic plc's Q2 earnings show moderate growth, highlighting potential for shareholder value through strategic initiatives.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.85, along ...

Diabetes shines, cardiac ablation stumbles, and new products spark hope--Medtronic's Q2 FY25 shakes up expectations.

Analysts are estimating that Medtronic will report an earnings per share (EPS) of $1.25. Investors in Medtronic are eagerly ...